CO5700746A2 - Beta-carbolinas utiles para tratar enfermedades inflamatorias - Google Patents

Beta-carbolinas utiles para tratar enfermedades inflamatorias

Info

Publication number
CO5700746A2
CO5700746A2 CO05113041A CO05113041A CO5700746A2 CO 5700746 A2 CO5700746 A2 CO 5700746A2 CO 05113041 A CO05113041 A CO 05113041A CO 05113041 A CO05113041 A CO 05113041A CO 5700746 A2 CO5700746 A2 CO 5700746A2
Authority
CO
Colombia
Prior art keywords
ring
aliphatic group
amino
halo
group
Prior art date
Application number
CO05113041A
Other languages
English (en)
Inventor
Michael E Hepperle
Original Assignee
Milenium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milenium Pharmaceuticals Inc filed Critical Milenium Pharmaceuticals Inc
Publication of CO5700746A2 publication Critical patent/CO5700746A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

1.- Un compuesto de fórmula I: o a una sal farmacéuticamente aceptable del mismo, donde:el Anillo A se selecciona entre el grupo compuesto por:(a) un anillo piridinilo o pirimidinilo que está sustituido con (i) -CH2C(O)-G y 0-1 R6a o (ii) 1-2 R6a, y(b) un anillo morfolinilo, piperidinilo, piperazinilo, pirrolidinilo, piranilo, tetrahidrofuranoilo, ciclohexilo, ciclopentilo o tiomorfolinilo que está sustituido con (i) -C(R9)3, -W-G o -G, (ii) 0-4 R6b y (iii) 0-1 grupos oxo sobre un carbono del anillo o 0-2 grupos oxo sobre un azufre del anillo;cada R6a se selecciona independientemente entre un grupo alifático C1-6, halo, alcoxi C1-6 o amino;cada R6b se selecciona independientemente entre un grupo alifático C1-3 o N(R7)2, y dos R6b sobre el mismo o un carbono adyacente se toman opcionalmente junto con el/los átomo(s) de carbono que intervienen para formar un anillo de 5-6 miembros que tiene 1-2 heteroátomos en el anillo seleccionados entre N, O o S;W es -Q-, -Q-C(O)-, -C(R9)2-C(R9)(R12)- o -C(R9)2-[C(R9)(R12)]2-;Q es -C(R9)2- o -C(R9)2C(R9)2-;G es -OH, -NR4R5, -N(R9)CONR4R5, -N(R9)SO2(un grupo alifático C1-3), -N(R9)COCF3, -N(R9)CO(un grupo alifático C1-6), -N(R9)CO(heterociclilo), -N(R9)CO(heteroarilo), -N(R9)CO(arilo), un anillo heterociclilo de 3-7 miembros o un heteroarilo de 5-6 miembros, donde cada uno de los restos heteroarilo, arilo y heterociclilo de G está opcionalmente sustituido con 1-3 R10;R1 es hidrógeno, halo, un grupo alifático C1-3, amino, ciano, (alquil C1-3)1-2 amino, alcoxi C1-3, -CONH2, -NHCOCF3 o -CH2NH2;R2 es hidrógeno, halo, un grupo alifático C1-3, -CF3;R3 es hidrógeno, halo, un grupo alifático C1-6, haloalquilo C1-6, alcoxi C1-6, hidroxi, amino, ciano o (alquil C1-6)1-2 amino; ...
CO05113041A 2003-04-09 2005-11-04 Beta-carbolinas utiles para tratar enfermedades inflamatorias CO5700746A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
CO5700746A2 true CO5700746A2 (es) 2006-11-30

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05113041A CO5700746A2 (es) 2003-04-09 2005-11-04 Beta-carbolinas utiles para tratar enfermedades inflamatorias

Country Status (22)

Country Link
US (2) US7727985B2 (es)
EP (1) EP1611134A1 (es)
JP (1) JP2006522824A (es)
KR (1) KR20060006031A (es)
CN (1) CN1802375A (es)
AU (1) AU2004230952A1 (es)
BR (1) BRPI0409263A (es)
CA (1) CA2521300A1 (es)
CO (1) CO5700746A2 (es)
CR (1) CR8042A (es)
EA (1) EA009121B1 (es)
EC (1) ECSP056145A (es)
HR (1) HRP20050926A2 (es)
MA (1) MA27837A1 (es)
MX (1) MXPA05010793A (es)
NI (1) NI200500174A (es)
NO (1) NO20054598L (es)
OA (1) OA13115A (es)
RS (1) RS20050832A (es)
TN (1) TNSN05257A1 (es)
WO (1) WO2004092167A1 (es)
ZA (1) ZA200508198B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.
TW200539880A (en) * 2004-04-09 2005-12-16 Millennium Pharm Inc Beta-carbolines useful for treating inflammatory disease
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2630562C (en) 2005-11-22 2013-12-31 Merck & Co., Inc. Tricyclic compounds useful as inhibitors of kinases
WO2007106884A2 (en) 2006-03-15 2007-09-20 Theralogics, Inc. Methods of treating muscular wasting diseases using nf-kb activation inhibitors
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
AR064307A1 (es) * 2006-12-13 2009-03-25 Gilead Sciences Inc Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
WO2009054965A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Salts of n- (6-chloro-9h-pyrido [3,4-b] ind0l-8-yl) -4- [2- (2, 6-dimethyl-4-morpholinyl) -2-0x0e thyl] -6, 6-dimethyl-morpholinecarboxamide
WO2009054970A1 (en) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Mesylate salt of an ikk inhibitor
EP2297347B1 (en) 2008-05-14 2017-03-08 Millennium Pharmaceuticals, Inc. Methods and kits for monitoring the effects of immunomodulators on adaptive immunity
US8299055B2 (en) 2008-10-02 2012-10-30 Asahi Kasei Pharma Corporation 8-substituted isoquinoline derivative and the use thereof
WO2011120911A1 (en) 2010-03-30 2011-10-06 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
KR101784284B1 (ko) * 2011-03-28 2017-10-11 에스제이티 몰레큘라 리서치, 에스.엘. 대사증후군 치료 화합물
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
CN108271369A (zh) 2015-10-23 2018-07-10 法尔玛赞公司 用于制备色胺及其衍生物的新工艺
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69925840T2 (de) * 1998-08-12 2006-05-04 Pfizer Products Inc., Groton Tace inhibitoren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
BR0109161A (pt) 2000-03-15 2002-11-26 Aventis Pharma Gmbh Beta-carbolinas substituìdas com atividade de inibição de ikb-quinase
WO2001068648A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
CA2460939C (en) * 2001-09-19 2008-07-29 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
WO2003039545A2 (en) * 2001-11-07 2003-05-15 Millennium Pharmaceuticals, Inc. Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers
JP2006519855A (ja) * 2003-03-07 2006-08-31 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニスト
MXPA05010793A (es) 2003-04-09 2005-12-05 Millennium Pharm Inc Beta-carbolinas utiles para tratar enfermedades inflamatorias.

Also Published As

Publication number Publication date
NO20054598L (no) 2005-10-27
EA200501584A1 (ru) 2006-06-30
CR8042A (es) 2006-05-30
EA009121B1 (ru) 2007-10-26
WO2004092167A1 (en) 2004-10-28
BRPI0409263A (pt) 2006-03-28
EP1611134A1 (en) 2006-01-04
OA13115A (en) 2006-11-10
CA2521300A1 (en) 2004-10-28
TNSN05257A1 (en) 2007-07-10
JP2006522824A (ja) 2006-10-05
MA27837A1 (fr) 2006-04-03
WO2004092167A8 (en) 2006-01-05
US7727985B2 (en) 2010-06-01
US20040235839A1 (en) 2004-11-25
KR20060006031A (ko) 2006-01-18
ZA200508198B (en) 2007-01-31
US20100093713A1 (en) 2010-04-15
ECSP056145A (es) 2006-04-19
AU2004230952A1 (en) 2004-10-28
HRP20050926A2 (en) 2006-06-30
NO20054598D0 (no) 2005-10-06
MXPA05010793A (es) 2005-12-05
CN1802375A (zh) 2006-07-12
NI200500174A (es) 2006-04-17
RS20050832A (en) 2007-12-31

Similar Documents

Publication Publication Date Title
CO5700746A2 (es) Beta-carbolinas utiles para tratar enfermedades inflamatorias
CO5611126A2 (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa
AR036492A1 (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
CO4970713A1 (es) Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
AR090649A2 (es) Inhibidores del virus de la hepatitis c
SE0104332D0 (sv) Therapeutic agents
TNSN07471A1 (en) Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
AR035362A1 (es) Compuestos inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona, composiciones farmaceuticas, y metodos de tratamiento con dichos compuestos
NO20063323L (no) Pyrido- og pyrimidopyrimidinderivater
CA2545427A1 (en) Selective kinase inhibitors
NO20056196L (no) Makrocykliske kinazolinderivater som antiproliferative midler
DE69203545D1 (de) 2,4,6-Triaminopyrimidin-N-Oxidderivate enthaltende Zusammensetzungen zur Verwendung beim Vermindern des Haarausfalles sowie zum Auslösen und Anregen des Haarwuchses und neue 2,4,6-Triaminopyrimidin-N-Oxidderivate.
AR056886A1 (es) Compuestos de pirrolopiridina sustituida inhibidores de quinasas, composiciones farmaceuticas que los contienen y usos en el tratamiento del cancer
PE107898A1 (es) Compuestos 1,3-diheterociclicos, inhibidores de metaloproteasa
SE0301446D0 (sv) New Compounds
SE0403171D0 (sv) New compounds
AR058110A1 (es) Derivados de piperidina
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
AR041689A1 (es) Derivados de piridoindolona substituidos en 3- por un fenilo su preparacion y su aplicacion en terapeutica
AR069700A1 (es) Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
DK0732332T3 (da) Substituerede benzothienylpiperaziner, deres anvendelse som lægemidler og fremgangsmåder til fremstilling deraf
NO20032314D0 (no) Nye desloratadinsalter, fremgangsmåte for deres syntese og farmasöytiske preparater derav
DK0812838T3 (da) Pyridoncarboxylsyrederivater substitueret med bicyclisk aminogruppe, estere og salte deraf og bicyclisk amin som mellemprodukt

Legal Events

Date Code Title Description
FC Application refused